NASD
| Health Care |
Biotechnology
Valneva SE (VALN)
LAST (2 Apr, 10:04 AM ET)
Extended HOURS (00:00 PM ET)
MARKET CAP
VOLUME
| Open | 6.88 |
| Previous Close | 6.76 |
| Day Range | 6.88 - 6.94 |
| 52-Week Range | 3.62 - 9.50 |
| All-Time High | 67.84 |
| Avg. Volume (50-day) | 48,649.1 |
| EPS (TTM) | -0.08 |
| Next Earnings Date | 2025-08-12 |
| Last Earnings Date | 2025-03-20 |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | No |
| P/E Ratio | -88.37 |
| PEG Ratio | 0.06 |
| Price to Book | 2.92 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | 183.33 M |
| Revenue per Share (TTM) | 2.26 |
| Shares Outstanding | 81.199 M |
| Share Float (%) | 80.89 M |
| % Held by Institutions | 0.89 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 7 (-1.00%) |
| +/- SMA(50) | 6.73 (+2.97%) |
| +/- SMA(200) | 6.17 (+12.32%) |
| 5-Day Perf. | -3.21% |
| 1-Month Perf. | +2.67% |
| 3-Month Perf. | +46.82% |
| 6-Month Perf. | +20.94% |
| YTD Perf. | +58.51% |
| 1-Year Perf. | -10.23% |
| RSI(14) | 50.43 |
| ATR(14) | 0.37 |
| ADX(14) | 15.16 |
| Beta (5Y) | 1.00 |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
VALN
Valneva SE
Sector: Health Care
Industry: Biotechnology
Employees: 713
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
VALN has triggered the following predefined scans:
| No Recent Scan Appearances |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
